Baseline tumor burden predicts the efficacy of first-line chemoimmunotherapy in patients with advanced non-small cell lung cancer: results from 2 phase 3 randomized placebo-controlled trials

ABSTRACT:

SUBMITTER: He X 

PROVIDER: S-EPMC12382186 | biostudies-literature | 2025 Jan

REPOSITORIES: biostudies-literature